Maganti Lab

A multi-disciplinary approach to understand Hematopoietic Stem Cell biology

Our Team

Team Leader / Principal Investigator

Dr. Harinad (Hari) Maganti PhD

Scientist, Innovation & Portfolio Management Department at Canadian Blood Services [Read more]

Adjunct Professor, Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa [Read more]

PubMed

Training:

MSc (Dr. Jian Ping Xu) McMaster University, Hamilton, ON, Canada

PhD (Dr. William Stanford) at the University of Ottawa, Ottawa, ON, Canada

Postdoctoral fellow (Dr. Freda Miller) at SickKids (2018 – 2020)

Postdoctoral fellow (Dr. Nicolas Pineault) at Canadian Blood Services (2020 – 2022)

Current Members:

Dhuha Hassan MD

Research Assistant

MD at School of Medicine, Avalon University, Willemstad, Curaçao

Project: Screening of RNA methylase inhibitors in hematopoietic stem and progenitor cells; Logistical support

PubMed

Tanvir Hasan MBBS MSc

Research Assistant

MBBS at Khulna Medical College, Rajshahi University, Bangladesh

MSc at the University of Ottawa, Ottawa, ON, Canada

Project: Impact of RNA demethylase ALKBH5 on hematopoietic stem and progenitor cell regulation (In collaboration with Dr. Nicolas Pineault)

PubMed

Ajay Rantan Pasala MSc

PhD candidate, University of Ottawa

MSc at the University of Eastern Piedmont, Novara, Italy

Project: Impact of RNA demethylase FTO on hematopoietic stem and progenitor cell regulation

PubMed

Justine Hanotaux B.Eng. M.Eng.

PhD student (starting Fall 2024), University of Ottawa

B.Eng. at Polytech Sorbonne, Université Pierre et Marie Curie, Paris, France

M.Eng. at Polytech Clermont, Université Clermont Auvergne, Auvergne, France

Project: Accelerating gene editing therapies for patients with sickle cell disease

PubMed

Bryenah Bennett

Summer student

Project: Characterizing the interacting partners of FTO

PubMed

Annaëlle Dupont

Summer exchange student

M.Eng. at Polytech Clermont, Université Clermont Auvergne, Auvergne, France

Project: Engineering HSCs for “off the shelf” immune therapies for treating Acute Myeloid Leukemia